- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- Science Education Progress
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
End-of-the-Week Review: Anthrax, Booger, Carbon, and Drugs
Some of the interesting blogs that caught our attention this week:
Effect Measure goes where few other dare and questions the validity of the Ivins fiasco, not once but twice this week. The evidence is the same as what the mainstream media presents, but the authors arrive at a different conclusion from the FBI’s.
Joe Romm, writing at Science Blog’s Next Generation of Energy Ideas blog, explains that if we don’t stem the flood of carbon pouring out of coal-fired power plants, nothing else we do to stop climate change will matter.
Mira Kolodkin at SEA’s blog covers the FDA’s inability to adequately follow up on illegal uses of drugs and comments on the GAO’s suggestion of a tracking system to help the FDA respond to complaints of violations more efficiently.
Brandon Keim at Wired touches on the bioethical implications of cloning Booger and comments on misconceptions about personhood. He explains that Booger, like people, was more than his genes.
Comments on this article
